References
- Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007;167:2207--2212
- Muth P, Metz R, Siems B, et al. Sensitive determination of nitrofurantoin in human plasma and urine by high-performance liquid chromatography. J Chromatogr A 1996;729:251–258
- Rogers RG, Kammerer-Doak D, Olsen A, et al. A randomized, double-blind, placebo-controlled comparison of the effect of nitrofurantoin monohydrate macrocrystals on the development of urinary tract infections after surgery for pelvic organ prolapse and/or stress urinary incontinence with suprapubic catheterization. Am J Obstet Gynecol 2004;191:182–187
- Alexiou Z, Mouktaroudi M, Koratzanis G, et al. The significance of compliance for the success of antimicrobial prophylaxis in recurrent lower urinary tract infections: the Greek experience. Int J Antimicrob Agents 2007;30:40–43
- Arya SC, Agarwal N, Agarwal S. Nitrofurantoin: an effective and ignored antimicrobial. Int J Antimicrob Agents 2006;27:354--355
- Vahlensieck Jr W, Westenfelder M. Nitrofurantoin versus trimethoprim for low-dose long-term prophylaxis in patients with recurrent urinary tract infections. Int Urol Nephrol 1992;24:3–10
- Karlowsky JA, Thornsberry C, Jones ME, Sahm DF. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin Infect Dis 2003;36:183–187
- Kashanian J, Hakimian P, Blute M, et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int 2008;102:1634–1637
- Bates TR, Young JM, Wu CM, Rosenberg HA. pH-dependent dissolution rate of nitrofurantoin from commercial suspensions, tablets, and capsules. J Pharm Sci 1974;63:643–645
- Paul HE, Hayes KJ, Paul MF, Borgmann AR. Laboratory studies with nitrofurantoin. Relationship between crystal size, urinary excretion in the rat and man, and emesis in dogs. J Pharm Sci 1967;56:882–885
- Koradia V, de Diego HL, Elema MR, Rantanen J. Integrated approach to study the dehydration kinetics of nitrofurantoin monohydrate. J Pharm Sci 2010;99:3966–3976
- Otsuka M, Teraoka R, Matsuda Y. Characterization of nitrofurantion anhydrate and monohydrate, and their dissolution behaviors. Chem Pharm Bull 1990;38:833–835
- Ali A, Gorashi A. Absorption and dissolution of nitrofurantoin from different experimental formulations. Int J Pharm 1984;19:297–306
- Stoll RG, Bates TR, Swarbrick J. In vitro dissolution and in vivo absorption of nitrofurantoin from deoxycholic acid coprecipitates. J Pharm Sci 1973;62:65–68
- Patil J, Korachagaon A, Shiralashetti S, Marapur S. Enhancing dissolution rate of ziprasidone via co-grinding technique with highly hydrophilic carriers. J Pharm Sci 2012;2:26--32
- Sugimoto S, Niwa T, Nakanishi Y, Danjo K. Novel Ultra-Cryo Milling and Co-grinding technique in liquid nitrogen to produce dissolution-enhanced nanoparticles for poorly water-soluble drugs. Chem Pharm Bull 2012;60:325–333
- Li J, Liu P, Liu J-P, et al. Novel Tanshinone II a ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2012;80:426–432
- Otsuka M, Teraoka R, Matsuda Y. Physicochemical properties of nitrofurantoin anhydrate and monohydrate and their dissolution. Chem Pharm Bull 1991;39:2667–2670
- Aaltonen J, Strachan CJ, Pöllänen K, et al. Hyphenated spectroscopy as a polymorph screening tool. J Pharm Biomed Anal 2007;44:477–483
- Tian F, Qu H, Louhi-Kultanen M, Rantanen J. Mechanistic insight into the evaporative crystallization of two polymorphs of nitrofurantoin monohydrate. J Cryst Growth 2009;311:2580–2589
- Tian F, Baldursdottir S, Rantanen J. Effects of polymer additives on the crystallization of hydrates: a molecular-level modulation. Mol Pharm 2008;6:202–210
- Pienaar E, Caira M, Lötter A. Polymorphs of nitrofurantoin. I. Preparation and X-ray crystal structures of two monohydrated forms of nitrofurantoin. J Crystallogr Spectrosc Res 1993;23:739–744
- Otsuka M, Ishii M, Matsuda Y. Effect of surface-modification on hydration kinetics of nitrofurantoin anhydrate. Colloids Surf B Biointerfaces 2002;23:73–82
- Eyjolfsson R. Nitrofurantoin: particle size and dissolution. Drug Dev Ind Pharm 1999;25:105–106
- Murata S, Ueda S, Shimojo F, et al. In vivo performance of time-controlled explosion system (TES) in GI physiology regulated dogs. Int J Pharm 1998;161:161–168
- Narisawa S, Nagata M, Ito T, et al. Drug release behavior in gastrointestinal tract of beagle dogs from multiple unit type rate-controlled or time-controlled release preparations coated with insoluble polymer-based film. J Control Release 1995;33:253–260
- Gröning R, Cloer C, Georgarakis M, Müller RS. Compressed collagen sponges as gastroretentive dosage forms: in vitro and in vivo studies. Eur J Pharm Sci 2007;30:1–6
- Gröning R. Control of release and biological availability of drugs – investigations into the renal elimination of nitrofurantoin. Int J Pharm 1981;8:175–181
- Hoener B-a, Patterson SE. Nitrofurantoin disposition. Clin Pharmacol Ther 1981;29:808–816
- Otsuka M, Teraoka R, Matsuda Y. Physicochemical stability of nitrofurantoin anhydrate and monohydrate under various temperature and humidity conditions. Pharm Res 1991;8:1066–1068
- Rosenberg H, Bates T. The influence of food on nitrofurantoin bioavailability. Clin Pharmacol Ther 1976;20:227--232
- Alhamami OM. The effects of some physico-chemical factors and pharmaceutical excipients on the bioavailability of nitrofurantoin oily and aqueous suspensions in rats. Drug Dev Ind Pharm 2002;28:305–316